Cancer-driven granulo-monocytopoiesis stimulates expansion of tumor promoting myeloid populations, mostly myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs). We identified subsets of MDSCs and TAMs based on the expression of retinoic-acid-related orphan receptor (RORC1/RORg) in human and mouse tumor bearers. RORC1 orchestrates myelopoiesis by suppressing negative (Socs3 and Bcl3) and promoting positive (C/EBPb) regulators of granulopoiesis, as well as the key transcriptional mediators of myeloid progenitor commitment and differentiation to the monocytic/macrophage lineage (IRF8 and PU.1). RORC1 supported tumor-promoting innate immunity by protecting MDSCs from apoptosis, mediating TAM differentiation and M2 polarization, and limiting tumor infiltration by mature neutrophils. Accordingly, ablation of RORC1 in the hematopoietic compartment prevented cancer-driven myelopoiesis, resulting in inhibition of tumor growth and metastasis.
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In Brief
Strauss et al. show that RORC1 orchestrates myelopoiesis and supports tumor-promoting innate immunity. Importantly, ablation of RORC1 in the myeloid compartment inhibits tumor growth and metastasis, suggesting a cancer therapeutic approach.
INTRODUCTION
Immunologic stress, such as infection and cancer, modifies the magnitude and composition of the hematopoietic output, a feature of immune regulation defined as ''emergency'' hematopoiesis, to guarantee proper supply of immune cells to increased demand (Ueha et al., 2011) . Tumors can reprogram myeloid cells to promote disease progression (Sica and Bronte, 2007) . However, the molecular pathways guiding cancer-driven ''emergency'' myelopoiesis remain largely unknown. Colony-stimulating factors (CSFs) are major orchestrators of hematopoietic development. Among these, granulocyte CSF (G-CSF) and granulocyte-macrophage CSF (GM-CSF) drive ''emergency'' myelopoiesis by securing supply of neutrophils and macrophages from bone marrow (BM) and hematopoietic stem cell niches (HSCs) (Metcalf, 2008; Ueha et al., 2011) . Further, the macrophage CSF (M-CSF) promotes macrophage differentiation from medullar precursors and differentiation of tissue macrophages involved in tissue homeostasis (Hume and MacDonald, 2012) and tumor progression (Qian and Pollard, 2010) . Recent studies reveal that monocytic and granulocytic myeloid-derived suppressor cells (M-MDSCs and PMN-MDSCs, respectively) and tumor-associated macrophages (TAMs), the major myeloid populations associated with cancer development (Sica and Bronte, 2007) , differentiate from a common myeloid progenitor (CMP) (Gabrilovich et al., 2012) . Importantly, reciprocal regulation of macrophage versus neutrophil/granulocyte differentiation might control tissue homeostasis. Depletion of tissue macrophages leads to exacerbated G-CSF-mediated granulopoiesis (Gordy et al., 2011; Goren et al., 2009) , and tissue macrophages Significance Preclinical data show that MDSCs and TAMs orchestrate tumor-promoting conditions, suggesting these cells as attractive therapeutic targets. MDSC and TAM generation is tightly associated with the altered hematopoietic output that occurs in cancer, defined as ''emergency hematopoiesis.'' Here we report that RORC1 is a key driver of emergency hematopoiesis in tumor bearers, in response to colony-stimulating factors (G-CSF, GM-CSF, and M-CSF), and that RORC1-expressing myeloid cells mark advanced cancer inflammation. We demonstrate that ablation of RORC1 in the myeloid compartment impairs tumor development and the generation of suppressive MDSCs while promoting generation of antitumor M1-polarized TAMs. Thus, inhibition of RORC1-dependent myelopoiesis may represent a therapeutic approach to prevent the induction of the tumor-promoting host macro-and micro-environments.
regulate HSC niche homeostasis (Chow et al., 2011; Winkler et al., 2010) . Thus, investigation of the molecular networks that dictate this reciprocal regulation appears to be crucial, as it may affect tissue homeostasis during cancerogenesis.
G-CSF-induced granulopoiesis is mediated through the transcription factors c-EBPb (Akagi et al., 2008) and STAT3 (Zhang et al., 2010) , whereas M-CSF supports monocyte differentiation through the transcription factors PU.1 and IRF8 (Friedman, 2007) . Of relevance, interleukin-17A (IL-17A) promotes G-CSF-and stem-cell-factor-mediated neutrophilia (Liu et al., 2010) and supports G-CSF-driven ''emergency'' myelopoiesis (Schwarzenberger et al., 2000) .
Despite the fact that IL-17 expression in cancer has been so far mainly restricted to the adaptive immunity (Iwakura et al., 2011) and its role in cancer remains controversial (Toomer and Chen, 2014) , TAMs and MDSCs produce the Th17-driving cytokines TGFb and IL-6 (Zamarron and Chen, 2011) , and IL-17-expressing cells with macrophage morphology have been described in cancer patients (Zhu et al., 2008) . Although the Th17 response is controlled by the orphan nuclear receptor retinoic-acid-related orphan receptor gamma (RORg) full-length protein (RORC1) and the RORCgt splice variant (RORC2) (Ivanov et al., 2006) , the signaling pathways that drive IL-17-producing innate immune cells have been poorly investigated. IL-17A-expressing myeloid cells have been reported in inflammation (Taylor et al., 2014; Zhu et al., 2008; Zhuang et al., 2012) . In arthritis patients, mast cells express a dual RORC1/IL-17A fingerprint in response to TLR4 ligands (Hueber et al., 2010) , and a population of RORgt-expressing neutrophils that produce IL-17 was identified in fungal infection (Taylor et al., 2014) . We explored the role of the IL-17/RORC1 axis in myeloid lineage differentiation and commitment associated with cancer development.
RESULTS

Divergent RORC1/IL-17A Fingerprint in Tumor-Associated Myeloid Cells
To clarify the role of IL-17A + innate immune cells in tumor progression, we screened the myeloid compartment of fibrosarcoma (MN/MCA1)-bearing C57BL/6 mice. A tumor volume of <1.5 cm 3 and few lung metastases (fewer than five), at days 21-23 after tumor cell injection, was defined as early-stage disease (ED), whereas tumors larger than 2 cm 3 and a higher number of lung metastases (more than 15; days 25-28) was defined as advanced-stage disease (AD) ( Figure S1 ). In AD, few blood and spleen CD45 + CD3 + T cells expressed IL-17A (data not shown), whereas IL-17A was significantly expressed by CD45 + CD3
À cells in the blood (30% ± 3%) and spleen (12% ± 1.5%) ( Figure 1A (Mantovani et al., 2011) . In contrast, IL-17A was poorly or not expressed by M-MDSCs ( Figure 1C ) and CD11b + F4/80 + macrophages (data not shown). RORC1 and its splice variant RORC2 are master regulators of IL-17A gene transcription in Th17 cells (Ivanov et al., 2006) , innate lymphocytes (Sawa et al., 2010) , gd T cells (Gray et al., 2011) , and natural killer T cells (Rachitskaya et al., 2008 ). Hence, we tested by FACS whether IL-17 expression in myeloid cells was associated with RORC1. In keeping with IL-17A expression, the majority of blood and spleen PMN-MDSCs from AD mice expressed RORC1, while its expression was restricted to a minor subset of IL-17A À M-MDSCs ( Figure 1D , left). Nevertheless, as compared to PMN-MDSCs, M-MDSCs expressed higher levels of RORC1, estimated as mean fluorescence intensity (MFI) (Figure 1D, right) . It is noteworthy that RORC1 was highly expressed by splenic IL-17A
À
CD11b
+ F4/80 + macrophages in AD mice (Figure 1E) , by F4/80 + TAMs (>90%) and thyoglicollate-elicited peritoneal macrophages (PECs) from both tumor-free (NT-PEC) and AD (AD-PEC) mice ( Figure 1E ). To corroborate the evidence that ED stages already promote emergency hematopoiesis, we performed histopathological and immunohistochemical analysis of both spleens and BM from mice bearing early-and late-stage tumor (Figure 2A ). Histopathological analysis of the BM parenchyma of wild-type (WT) and Rorc1 À/À tumor-free and tumor-bearing mice (including ED and AD tumor stages) showed a significant expansion of the granulocytic compartment (Figure 2A , top), which associated with a progressive contraction of the erythroid colonies (blue arrows) and with signs of dysmegakaryopoiesis (i.e., megakaryocytes with bulbous and/or hypolobated nuclei and prominent pleiomorphism; red arrows). Notably, at late time points (AD), the BM granulocytic hyperplasia of tumor-associated emergency hematopoiesis was characterized by the enrichment in immature myeloid precursors (Figure 2A , top, dashed lines), which were more conspicuous in WT than in Rorc1 À/À mice. As expected, tumor-free mice showed a normal composition of the hematopoietic parenchyma in the BM with preserved myeloid/erythroid ratio and normal maturation of the myeloid elements. Spleen histopathology performed on the same animals demonstrated signs of tumor-associated emergency hematopoiesis in the spleen parenchyma of ED and AD tumor-bearing WT and Rorc1
mice, in the form of red pulp hyperplasia underlying splenomegaly (Figure 2A , bottom). The enhanced myelopoiesis of WT mice featured the progressive (i.e., from ED to AD) accumulation of clusters of morphologically immature granulocytes ( Figure 2A , bottom, arrows and dashed lines; right H&E insets) that intermingled with erythroid precursor islets, megakaryocytes, and polymorphonuclear granulocytes. Despite a comparable degree of red pulp hyperplasia due to the consistent increase in polymorphonuclear granulocytes, erythroid precursors, and megakaryocyte clusters, Rorc1 À/À mice showed less clusters of morphologically immature myeloid cells as compared with their WT counterparts ( Figure 2A , bottom, arrows and dashed lines; right H&E insets). Immunohistochemical analysis of the MDSCassociated IL-4R marker highlighted IL-4R + myeloid cells with monocytoid or granulocytic morphology populating the myeloid cell aggregates differently enriched within the expanded red pulp of tumor-bearing WT and Rorc1 À/À mice ( Figure 2A ). Overall, these results demonstrate that Rorc1 À/À mice effectively instruct BM and splenic emergency hematopoiesis along cancer development while displaying a defective induction of specific MDSC-related myeloid populations. With the gating strategy used to determine IL-17A and RORC1 shown in Figure 2B , our results suggest that RORC1 expression is uncoupled from IL-17A in the monocytic/macrophage compartment, while it is co-expressed in the granulocytic cells of tumor-bearing mice. To validate this finding in cancer patients, we analyzed the MDSC populations in PBMCs from healthy donors (HDs; n = 10) or patients with advanced colorectal cancer (CRC; stage II/III; n = 10) using the gating strategy of Figure 2C Figure 2D ). Expansion of MDSC populations in cancer patients was paralleled by an increased number of circulating neutrophils and monocytes ( Figure 2D ). Also in analogy to the murine setting ( Figure 1D ), the human M-MDSC population showed higher mean fluorescence intensity of RORC1 + . In contrast, IL-17A was detected neither in human blood M-MDSCs nor in PMN-MDSCs (data not shown). These results indicate that expression of RORC1 by myeloid subsets constitutes a hallmark of tumor-promoting ''emergency'' myelopoiesis.
RORC1 Promotes Expansion of MDSCs and TAMs
To investigate the in vivo relevance of RORC1-expressing myeloid cells, we transplanted donor RORC1-deficient BM cells into lethally irradiated C57BL/6 WT recipient mice (Rorc1 À/À >WT), to be compared to WT>WT mice. Eight weeks later, mice were injected with MN/MCA1 cells and monitored for tumor development. Tumor growth and metastasis were significantly reduced in Rorc1
>WT mice ( Figure 3A ). The effect of RORC1 deficiency in BM cells was tested in two additional tumor models. Rorc1 À/À BM was transplanted into mouse mammary tumor virus-polyoma middle T antigen (MMTV-PyMT; a spontaneous mammary carcinoma [Guy et al., 1992] ) transgenic mice and into C57BL/6 mice that were exposed to methylcholanthrene-induced cancerogenesis and subsequently developed fibrosarcoma (Stutman, 1974) (Figure 3B) . Consistently, RORC1 deficiency in the BM resulted in tumor growth inhibition in both models ( Figure 3B ). FACS analysis (data not shown) confirmed the IL-17/RORC1 expression pattern observed in the MN/MCA1 model (Figure 1 ). Rorc1 tumor-bearing mice showed a significant reduction of splenic M-MDSCs and PMN-MDSCs, in comparison to WT>WT mice ( Figure 3C ). To estimate the suppressive activity of M-MDSCs, we activated cells with IFN-g (Gabrilovich et al., 2012) , loaded them with ovalbumin, and then co-cultured them for 3 days with total splenocytes purified from OT-1 transgenic mice expressing the T cell receptor specific for the ovalbumin antigen. Rorc1 À/À M-MDSCs displayed reduced suppressive activity, estimated as proliferation of co-cultured OT1 splenocytes (Figure 3D) . It is noteworthy that, at the tumor site, we observed an increase of PMN-MDSCs ( Figure 3E ), as opposed to a significant decrease of CD11b + Ly6C low F4/80 + TAMs ( Figure 3F ). Histological analysis of spleens from Rorc1-deficient tumor bearers showed a dramatic reduction in IL-4R + MDSCs and strongly reduced expression of IL-17A ( Figure 3G >WT chimeras and, in accordance, a decrease of granulocyte/macrophage progenitors (GMPs) ( Figure 4A ). These findings reveal a blockage in differentiation of early hematopoietic progenitors in Rorc1 À/À >WT chimeras and suggest a relevance of RORC1 directly in the BM during the early steps of myeloid cell differentiation. Corroborating this hypothesis, RORC1 was expressed by immature (c-kit + ) granulocytes and monocytes in the BM of naive mice ( Figure 4B ). In the same myeloid cell subsets, IL-17 was found produced mainly by immature neutrophils ( Figure 4B ). Next, we tested the in situ expression of IL-17A and RORC1 in BM parenchyma of patients undergoing a biopsy for staging of Hodgkin's lymphoma. Consistently, IL-17A staining was localized within myeloid cells with immature morphology, within the precursor-rich areas lining the bone trabeculae ( Figure 4C , black arrows). By contrast, mature granulocytes with segmented nuclei barely expressed or did not express IL-17A. Indeed, a neat decreasing gradient was observed in IL-17A expression from para-trabecular areas rich in precursors toward intertrabecular spaces mainly populated by mature elements (Figure 4C) . Notably, double-marker immunohistochemical analysis confirmed that IL-17A + hematopoietic cells did not correspond to Th-17 cells, as they were distinct from the CD3 + T elements populating the BM niche ( Figure 4D , black arrows). Within the same BM hematopoietic parenchyma, RORC1 (RORg) expression was detected mostly in myeloid cells with combined cytoplasmatic and nuclear localization ( Figure 4E , black arrows). These results in human samples further support that the RORC1/ IL-17A program takes part in the regulation of the precursor showing the progressive changes in BM hematopoietic parenchyma along tumor development in the two strains. While tumor-free mice displayed a normal hematopoietic composition with no detectable differences between WT and Rorc1 À/À strains, ED and AD BM samples showed a progressive expansion of the myeloid granulocytic lineage, which was paralleled by the contraction of the erythroid (blue arrows) and megakaryocytic (red arrows) compartments and was similarly observed in WT and Rorc1 À/À mice. In AD samples, the myeloid pool expansion was also characterized by the increase in morphologically immature myeloid cell clusters (dashed lines), which was consistent with the enhanced myelopoietic activitiy of stress-adapted (i.e., cancer-associated) myelopoiesis. The immature myeloid cell clusters characterizing AD samples were more prominent in WT than in Rorc1 À/À mice. Original magnifications of H&E panels are 3400.
Bottom: spleen histopathological analysis of WT (left) and Rorc1 À/À (right, composite panels) tumor-free (upper panels) and tumor-bearing (ED, middle composite panels; AD, lower composite panels) mice showing the progressive increase in red pulp (RP) hematopoietic function along tumor development in the two strains. In tumor-free mice, white pulp (WP) areas are predominant over RP, the latter being mainly populated by erythroid cells with scattered myeloid and megakaryocytic elements (upper H&E panels and upper H&E insets). In ED and AD samples, RP hyperplasia was evident and consequent to the increase of hematopoietic foci. In particular, the RP WT mice showed an increase in immature myeloid cell figures (left middle and lower H&E panels, arrows and dashed lines) showing granulocytic or monocytoid morphology (left middle and lower H&E insets, arrows), along with an increase in megakaryocyte and erythroid precursor clusters. In Rorc1 À/À mice, despite a comparable degree of RP hyperplasia mainly consequent to megakaryocyte and polymorphonuclear granulocyte expansion and clustering, foci of morphologically immature myeloid cells were less evident (right middle and lower H&E panels and insets, arrows and dashed lines These results indicated a key role of RORC1 in the myelopoietic activity of G-CSF and GM-CSF. Figure S3A underlies the different effects of G-CSF and GM-CSF on the differentiation of Ly6G + subsets, indicating that GM-CSF promotes a larger expansion of double Ly6G + Ly6C + monocytic cells.
We next determined whether RORC1 might control MDSC survival (Sinha et al., 2011) and maturation. Small differences were observed in survival of WT versus Rorc1
MDSCs at steady-state conditions (medium) ( Figure S3B ). In contrast, increased AnxV + binding was observed in both M-MDSCs and PMN-MDSCs after 48 hr, which was reduced in the presence of either tumor supernatant (TSN) or combination of GM-CSF/G-CSF in both subsets ( Figure S3B ), indicating that RORC1 is crucial for MDSC survival. The protective role of both TSN and GM-CSF/G-CSF against apoptosis was partially lost in RORC1-deficient M-MDSCs, while RORC1-deficient PMN-MDSCs suffered a massive apoptosis ( Figure S3B ). These results confirm the protective role of RORC1 in CSF-mediated M-MSDC and PMN-MDSC survival, highlighting a tighter dependence of PMN-MDSC survival from RORC1 expression levels. Neutrophil activation and maturation is paralleled by upregulation of the FCgII and FCgIII receptors (CD32 and CD16, respectively) (Hogarth, 2002) and of the complement C5a receptor (C5aR) (Guo and Ward, 2005) . Splenic PMN-MDSCs from WT>WT tumor bearers expressed lower CD16/CD32 and C5aR levels than did PMN-MDSCs from Rorc1 À/À >WT mice ( Figure S3C ). Furthermore, WT splenic immature PMN-MDSCs expressed lower levels of CD16/CD32 and C5aR, as opposed to higher RORC1, when compared to mature thioglycollate-elicited neutrophils (Neu-PECs) ( Figure S3D ). These observations indicate that RORC1 might suppress neutrophil maturation, favoring immature PMN-MDSCs to support tumor promotion.
RORC1 Controls Critical Regulators of Myelopoiesis
To determine the tumor-derived factor/s that activate RORC1, we analyzed MN/MCA1 supernatants from AD mice for myeloid growth factors. TSNs were enriched in G-CSF, GM-CSF, and M-CSF and partially in IL-1b ( Figure 5A ). Of note, 48 hr of treatment with either a combination of GM-CSF and G-CSF or TSN induced IL-17A expression in BM-derived PMN-MDSCs and, to a lower extent, in M-MDSCs ( Figure 5B, left) . BM-derived M-MDSCs and PMN-MDSCs expressed basal RORC1 levels ( Figure 5B, right) , plausibly induced by GM-CSF and G-CSF used for their in vitro generation (Peranzoni et al., 2010) , which was increased by combination of GM-CSF and G-CSF (Figure 5B, right) . Confocal microscopy demonstrated that RORC1 expression and nuclear translocation was induced in naive PECs challenged for 72 hr with lipopolysaccharide (LPS), IL1b, G-CSF, GM-CSF, and M-CSF, but not by IFN-g ( Figure 5C ) or IL-6 (data not shown). Of note, we found increased levels of G-CSF and GM-CSF in the sera of AD mice (data not shown), as compared to ED mice, suggesting that RORC1-dependent emergency hematopoiesis is controlled by the extent of cancer-associated inflammation. Finally, we determined the mRNA levels for RORC1 and RORC2 (Ivanov et al., 2006; Yang et al., 2008) in PECs and in thymocytes (Sun et al., 2000) from healthy WT mice ( Figure S4A ). It is noteworthy that LPS-stimulated (72 hr) PECs expressed Rorc1 mRNA levels similar to those of WT thymocytes, but not Rorc2 mRNA. These data confirm that in cancer, the monocyte-macrophage lineage expresses a selective RORC1 fingerprint unlinked from IL-17A, whereas the granulocyte/neutrophil lineage expresses a dual RORC1/IL-17A signature. In support of RORC1 as a key driver of ''emergency'' granulo-monocytopoiesis, BMCD11b + Gr1 + granulocytes and BM-CD11b + Ly6C + monocytes from both LPS-and M-CSF-treated mice significantly increased RORC1 expression ( Figure S4B ).
To determine the in vivo role of myeloid growth factor/s, we treated MN/MCA1-bearing mice with neutralizing antibodies to G-CSF, GM-CSF, or the M-CSF receptor (M-CSFR/CSFR1) See also Figure S2 . (legend continued on next page) (Hume and MacDonald, 2012) . Inhibition of G-CSF and GM-CSF limited the accumulation of splenic PMN-MDSCs with no effect on M-MDSCs ( Figure 5D , left). In contrast, the anti-CSFR1 antibody decreased the number of F4/80 + spleen macrophages whereas, surprisingly, it induced a strong increase in splenic PMN-MDSCs. At contrast, the anti-G-CSF antibody significantly increased the CD11b + F4/80 + spleen macrophages. Confirming the relevance of myelopoiesis to cancer inflammation, neutralization of GM-CSF, G-CSF, or M-CSFR resulted in inhibition of tumor growth and metastasis ( Figure 5D , center and right). These findings suggest a reciprocal antagonistic regulation of the polymorphonuclear and monocytic lineages in CSF-driven ''emergency'' myelopoiesis in cancer.
To shed light on the mechanisms of RORC1-driven emergency myelopoiesis, we evaluated positive and negative transcriptional regulators in BM and spleens from WT>WT and Rorc1 À/À >WT tumor bearers. CCAAT/enhancer binding protein b (C/EBPb) is a major positive regulator of G-CSF-and GM-CSF-driven ''emergency'' myelopoiesis (Akagi et al., 2008) , whereas C/EBPa appears to be a major regulator of ''steady-state'' granulopoiesis and cooperates with PU.1 to ''emergency'' granulo-monocytopoiesis (Hirai et al., 2006; Jin et al., 2011) . We observed a mild but significant decrease of mRNA expression of PU.1, C/EBPb, and C/EBPa in spleens and BM from Rorc1
>WT tumor bearers, paralleled by decreased C/EBPb protein levels in splenic PMN-MDSCs and M-MDSCs ( Figure 6A ). Importantly, BM and spleens from Rorc1
>WT MN/MCA1 tumor bearers displayed increased mRNA levels of the suppressor of cytokine signaling-3 (Socs3) and the transcriptional co-regulator B cell leukemia/lymphoma 3 (Bcl3) ( Figure 6B ), both potent inhibitors of G-CSF-driven granulopoiesis (Croker et al., 2004; Kreisel et al., 2011) . In agreement with the IFN-g-mediated inhibition of G-CSF-driven neutrophilia (Ulich et al., 1988) , IFN-g induced a strong increase of Socs3 and Bcl3 mRNA in splenic PMN-MDSCs from Rorc1 À/À tumor bearers ( Figure 6B , right).
Finally, in accordange with the decreased number of macrophages found in spleen and tumor of Rorc1
>WT chimeras ( Figure 6C ), we observed a decreased number of IRF8-expressing CD11b + F4/80 + CD115 + macrophages ( Figure 6D ), which was confirmed by confocal microscopy in tumor tissues of Rorc1
>WT chimeras (data not shown). As M-CSFR/CD115 (Qian and Pollard, 2010 ) is a marker of terminally differentiated macrophages (Auffray et al., 2009) , this result indicates that RORC1 is required for the modulation of cell-fate switching factor(s) driving maturation of macrophages (Friedman, 2007) .
RORC1 Controls Polarization of Myeloid Cells
M-CSFR signaling modulates macrophage survival and differentiation (Qian and Pollard, 2010) and induces M2 macrophage polarization, a condition supporting tumor progression (Mantovani and Sica, 2010) . To evaluate RORC1 in the macrophage polarization, we analyzed the mRNA expression of prototypical M1 and M2 genes in AD-PECs, cells displaying an intermediate PEC versus a TAM phenotype and representing a good model to study M1-M2 polarization in cancer (Sica et al., 2000; Torroella-Kouri et al., 2009) Figure 7A ). Simiarly, RORC1-deficient PMN-MDSCs showed increased TNF-a and IL-1b mRNA levels and IL-1b secretion in response to LPS/IFN-g ( Figure 7B ). Thus, RORC1 acts as negative regulator of M1 and promoter of M2 cytokine genes. This observation was supported by the increased levels of pro-inflammatory cytokines (TNF-a and IL-1b) and growth factors (G-CSF, GM-CSF, and VEGF) in MN/MCA1 supernatants from Rorc1 (C) Expression and nuclear translocation of RORC1 in PECs exposed to IFN-g (200 U/ml), LPS (100 ng/ml), IL-1b (20 ng/ml), G-CSF (40 ng/ml), GM-CSF (40 ng/ml), and M-CSF (40 ng/ml). After 72 hr of in vitro activation, PECs were stained with anti-RORC1 antibody (red) or irrelevant rat immunoglobulin G (IgG). Nuclei were counterstained with DAPI (blue). Representative images are shown. Confocal microscopy analysis of RORC1 nuclear fluorescence intensity (nuclear coefficient) is shown on the right. Mean ± SEM from three independent experiments is shown. Statistical analysis: *p < 0.05, **p < 0.01, ***p < 0.001 (Student's t test). Figure S6B) . Moreover, the increase of tumor-infiltrating F4/80 + TNF-a + macrophages and CD4 + IFN-g + T cells in response to anti-G-CSF, observed in WT mice, was significantly reduced in Rorc1 À/À mice ( Figure S6C ), strengthening the hypothesis that G-CSF works through the induction of RORC1. Finally, to assess the role of myeloid-specific RORC1 in adaptive immunity against cancer, we depleted CD4 + and CD8 + T cells in both WT and Rorc1 À/À tumor-bearing mice. As a result, we observed a significant increase of lung metastasis in Rorc1
tumor-bearing mice treated with the anti-CD4/anti-CD8 antibodies ( Figure S6D ), suggesting that the protumor activity of RORC1 acts through both the innate and adaptive immunity.
DISCUSSION
We demonstrate that RORC1 fuels cancer-promoting inflammation by enhancing survival and expansion of CD16/32 low / C5aR low immature MDSCs, with reduced expression of M1 cytokines (IL-1b and TNF-a) and increased suppressive activity, and promoting terminal macrophage differentiation. Our study indicates that RORC1 impinges on cancer-driven myelopoiesis by suppressing negative (Socs3 and Bcl3) (Croker et al., 2004; Kreisel et al., 2011) and promoting positive (C/EBPb) (Hirai et al., 2006) transcriptional regulators of ''emergency'' granulopoiesis, while instating the expression of macrophage-specific transcription factors IRF8 and PU.1 (Friedman, 2007 (Wu et al., 2014) . Further, an inflammatory cascade encompassing the IL-1b-mediated production by IL-17 in gdT cells resulted in systemic G-CSF-dependent expansion of suppressive neutrophils and formation of breast cancer metastasis (Coffelt et al., 2015) . Our observation that IL-17 is selectively expressed, but not secreted by immature granulocyte/neutrophil subsets, does not support a direct role of myeloid-cell-derived IL-17 in the expansion of MDSCs during cancer development, but rather indicates that IL-17A is a hallmark of immature myeloid responses in cancer bearers. This notion is further supported by the observation that expression of IL-17 and RORC1 localizes within the immature myeloid cells precursor-rich areas lining the bone trabeculae of BM biopsies from patients under diagnosis of Hodgkin's lymphoma. Moreover, in contrast to Rorc1 À/À BM transplantation, chimeric mice receiving the Il17a À/À BM had no defect in developing tumor-associated myeloid cells, in both the BM and spleen (data not shown). It remains to be established whether IL-17A expression by circulating MDSCs is dependent on the disease stage, as we did not observe its expression in blood from T2/T3 CRC patients. Along with other reports, our observation highlights the relevance of members of the nuclear receptor superfamily in regulation of inflammation (Gerbal-Chaloin et al., 2013; Wittke et al., 2004) and suggests RORC1 as central regulator of cancer associated myelopoiesis and key driver of the protumor differentiation of MDSCs and TAMs.
EXPERIMENTAL PROCEDURES
More-detailed procedures can be found in the Supplemental Experimental Procedures.
Ethics Statement
The study was approved by the scientific board of Humanitas Clinical and Research Center and designed in compliance with Italian governing law, EU directives and guidelines, and the NIH Guide for the Care and Use of Laboratory Animals. Mice have been monitored daily and euthanized when displaying excessive discomfort. Cancer patients were enrolled in the study after signing Cancer Research Center Humanitas IRB-approved consent. Mice C57BL/6 mice were purchased from Charles River. RORC1 mutant mice (B6.129P2(Cg)-Rorc tm1Litt /J) (Sun et al., 2000) were donated by Dr. Dan Littman (New York University). MMTV-PyMT mice (Guy et al., 1992) were donated by Professor Guido Forni (University of Turin) and mated with C57BL/6 females to obtain the F1 C57BL/6-MMTV-PyMT strain. IL-17A-deficient mice were donated by Dr. Burkhard Becher (University of Zurich). All animal work was conducted under the approval of the Humanitas Clinical and Research Center, in accordance with Italian and EU directives and guidelines. , or WT BM cells were injected intravenously into 8-week-old lethally irradiated (two doses of 475 cGy) CD45.1 C57BL/6 WT male or C57BL/6-MMTV-PyMT female mice. 8 weeks later, BM engraftment was checked by staining of blood cells with PerCP-conjugated CD45.1 antibody and PE-conjugated CD45.2 antibody (BD Biosciences) and subsequent FACS analysis.
Tumor Models 10 5 murine fibrosarcoma (MN/MCA1) cells were injected intramuscularly in the left hind limb. Tumor growth was monitored three times a week with a caliper, starting from day 14. The models of chemically induce fibrosarcoma and mammary tumor virus-polyoma middle T antigen (MMTV-PyMT) transgenic mice are described in the Supplemental Experimental Procedures.
Cell Culture and Reagents
Lineage cell separation from BM, isolation of myeloid cells, and cell-culture conditions are described in the Supplemental Experimental Procedures.
Mixed-Lymphocyte Reaction
Mixed-lymphocyte reaction was performed as previously reported (Larghi et al., 2012) and as described in the Supplemental Experimental Procedures.
Patients
Ten patients with T2 or T3 CRC did not receive radiation or chemotherapy before sample collection.
Flow Cytometry
Detailed conditions and antibodies used in flow cytometry analysis are described in the Supplemental Experimental Procedures
Gating Strategy
Gating strategy for the identification of human MDSCs, neutrophils, and monocytes is described in the Supplemental Experimental Procedures.
Histopathological Analysis
Histopathological analysis was performed on BM and spleens from WT, Rorc1
, and chimeric mice on sections routinely stained with H&E. Singleand double-marker immunohistochemistry on mouse and human tissue specimens were performed as previously reported (Tripodo et al., 2012) and are described in detail in the Supplemental Experimental Procedures.
Confocal Microscopy
Confocal Microscopy was performed as previously reported (Moalli et al., 2010) and as described in the Supplemental Experimental Procedures.
Statistics
Statistical significance was determined by a two-tailed Student's t test (*p < 0.05, ** p < 0.01, *** p < 0.001).
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